Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.

CONCLUSIONS: These safety and efficacy results support use of dupilumab as continuous long-term treatment for children aged ≥6 to <12 years with severe AD.
PMID: 32969489 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - September 23, 2020 Category: Dermatology Authors: Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP, Kamal MA, O'Malley JT, Patel N, Graham NMH, Bansal A Tags: Br J Dermatol Source Type: research